Summary of Key Points Core Viewpoint - The announcement details the extension of share pledges by the major shareholder of Guangzhou Kingmed Diagnostics Group Co., Ltd., indicating a significant portion of shares are pledged, which may impact the company's financial stability and investor confidence. Group 1: Share Pledge Details - The shareholder, Shengyutang, directly holds 21,000,000 shares, accounting for 4.53% of the total share capital of the company [1] - The current extension involves 8,580,000 shares, which represents 40.86% of Shengyutang's directly held shares and 1.85% of the company's total share capital [1] - After the extension, the total pledged shares by the controlling shareholder and related parties amount to 31,580,000 shares, which is 19.14% of their total holdings and 6.82% of the company's total share capital [1][6] Group 2: Pledge Status and Implications - As of the announcement date, the controlling shareholder, Liang Yaoming, and his associates have a cumulative pledge of shares, which includes Shengyutang and other investment partnerships [2] - The total number of pledged shares is 164,983,621, representing 35.61% of the total share capital, with 31,580,000 shares newly pledged [6] - The company will closely monitor the developments regarding these pledges and will disclose relevant information in accordance with regulations [6][7]

分季度来看：公司2024 年单四季度实现营业收入15.71 亿元，同比下降-29.57%，实现归母净利润-4.75 亿元，同比下降805.23%，实现扣非净利润-3.16 亿元，同比下降1,536.44%。单季度收入有所下降，主 要受DRG 推进、市场竞争等因素影响，市场需求增长放缓等因素影响，当期利润出现明显波动，一是 因部分应收账款回款周期延长，导致产生信用减值损失金额较大，二是公司对丧失使用功能的固定资产 进行报废处置，产生一定处置损失，三是公司投资的部分企业业务增长未能符合预期，造成减值损失及 公允价值变动损失。2025Q1 因市场需求未完全恢复，公司表观业绩仍有承压。 费用端：公司2024 年销售费用率12.94%，同比增长1.06pp；管理费用率8.32%，同比下降0.05pp；研发 费用率5.57%，同比增长0.10pp；财务费用率-0.04%，同比下降0.03pp，费用投入整体来看相对稳定；公 司2024 年毛利率33.15%，同比下降3.33pp，主要因收入规模下降，固定成本摊销增大，同时也与行业 竞争加剧外包价格变动有关；2024 年公司净利率-5.77%，同比下降13.23pp。 事件： ...